Repligen Corporation with ticker code (RGEN) have now 13 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $211.00 and $148.00 and has a mean target at $180.31. Now with the previous closing price of $182.10 this would imply there is a potential downside of -1.0%. The 50 day MA is $152.20 and the 200 day MA is $160.03. The market cap for the company is 10.10B. The stock price for the company is currently $180.93 USD
The potential market cap would be $10,002,110,249 based on the market consensus.
The company has a dividend yield of 5.38%. Other points of data to note are a P/E ratio of 89.57, revenue per share of $12.04 and a 2.08% return on assets.
Repligen Corporation is a life sciences company, which develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company’s bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins. The Filtration products are used in process development and process scale production. The Chromatography franchise includes products used in downstream purification, development, and manufacturing of biological drugs. The Process Analytics products allow end-users to make in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins franchise is represented by its Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all monoclonal antibody (mAb) based drugs on the market.
